Searchable abstracts of presentations at key conferences in endocrinology

ea0090p364 | Diabetes, Obesity, Metabolism and Nutrition | ECE2023

Metformin Ameliorates Fatty Liver Disease in A High-Fat Diet-Induced Obese FVB/N Mouse Model

Lozano de la Haba Samanta , Herman-Sanchez Natalia , Ojeda Perez Betsaida , Garcia-Estrada Antonio , Sarmento-Cabral Andre , M Luque Raul , Gahete Manuel D.

Objectives: Previous studies have shown that metformin can reduce high-fat diet (HFD)-induced body weight gain and fat accumulation in the liver. However, the results obtained in animal models regarding the implication of metformin in the modulation of other whole-body and tissue-specific parameters, are controversial or need to be further explored. Consequently, we aimed to explore the capacity of metformin in modulating glucose/insulin metabolism, liver function, adiposity, ...

ea0099p456 | Diabetes, Obesity, Metabolism and Nutrition | ECE2024

Ghrelin system as a novel source of biomarkers and therapeutic tools in metabolic liver diseases

Garcia-Estrada Antonio , Herman-Sanchez Natalia , Ojeda Perez Betsaida , Cordoba-Chacon Jose , Sarmento-Cabral Andre , Rodriguez-Peralvarez Manuel , M. Luque Raul , Luis Lopez-Canovas Juan , D. Gahete Manuel

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the main hepatic manifestation of obesity. MASLD was recently defined as liver steatosis in the presence of at least one cardiometabolic risk factor and reduced or absent alcohol intake. MASLD prevalence is rapidly increasing, thus becoming the fastest growing aetiology of the most common primary liver cancer, hepatocellular carcinoma (HCC), and the leading cause of liver transplantation in HCC patients. Curre...